Protection from anthrax toxin-mediated killing of macrophages by the combined effects of furin inhibitors and chloroquine

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 9, 2005, Pages 3875-3882

  Komiyama, Tomoko ^a   Swanson, Joel A ^a   Fuller, Robert S ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLARGINYLGLUTAMYLLYSYLBOROARGININE PINANEDIOL; ANTHRAX TOXIN; ARGINYLARGINYLASPARTIC ACID EGLIN; ARGINYLARGINYLASPARTYLGLYCINE EGLIN; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; BORONIC ACID DERIVATIVE; CHLORINE DERIVATIVE; CHLOROMETHYLKETONE INHIBITOR; CHLOROQUINE; EDEMA FACTOR; EGLIN C; FURIN INHIBITOR; KETONE DERIVATIVE; LETHAL FACTOR PROTEIN; METHYL GROUP; PEPTIDE DERIVATIVE; PROTEINASE; PROTEINASE INHIBITOR; RECOMBINANT ANTIGEN; UNCLASSIFIED DRUG;

ACIDITY; ANTHRAX; APOPTOSIS; ARTICLE; BINDING AFFINITY; CELL KILLING; CELL SURFACE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; ENDOCYTOSIS; LETHAL GENE; MACROPHAGE; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN ENGINEERING;

ALGORITHMS; ANIMALS; ANTIGENS, BACTERIAL; ANTIMALARIALS; BACTERIAL TOXINS; BLOTTING, WESTERN; CELLS, CULTURED; CHLOROQUINE; FURIN; L-LACTATE DEHYDROGENASE; MACROPHAGES; MICE; PROTEINS; RECEPTORS, CELL SURFACE; SERPINS;

EID: 24144450316     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.9.3875-3882.2005     Document Type: Article

References (42)

1. Abrami, L., S. Liu, P. Cosson, S. H. Leppla, and F. G. van der Goot. 2003. Anthrax toxin triggers endocytosis of its receptor via a lipid raft-mediated clathrin-dependent process. J. Cell Biol. 160:321-328.
2. Angliker, H. 1995. Synthesis of tight binding inhibitors and their action on the proprotein-processing enzyme furin. J. Med. Chem. 38:4014-4018.
3. Angliker, H., P. Wikstrom, E. Shaw, C. Brenner, and R. S. Fuller. 1993. The synthesis of inhibitors for processing protcinases and their action on the Kex2 proteinase of yeast. Biochem. J. 293:75-81.
4. Artenstein, A. W., S. M. Opal, P. Cristofaro, J. E. Palardy, N. A. Parejo, M. D. Green, and J. W. Jhung. 2004. Chloroquine enhances survival in Bacillus anthracis intoxication. J. Infect. Dis. 190:1655-1660.
5. Beauregard, K. E., R. J. Collier, and J. A. Swanson. 2000. Proteolytic activation of receptor-bound anthrax protective antigen on macrophages promotes its internalization. Cell. Microbiol. 2:251-258.
6. Bradley, K. A., J. Mogridge, M. Mourez, R. J. Collier, and J. A. Young. 2001. Identification of the cellular receptor for anthrax toxin. Nature 414:225-229.
7. Bravo, D. A., J. B. Gleason, R. I. Sanchez, R. A. Roth, and R. S. Fuller. 1994. Accurate and efficient cleavage of the human insulin proreceptor by the human proprotein-processing protease furin. Characterization and kinetic parameters using the purified, secreted soluble protease expressed by a recombinant baculovirus. J. Biol. Chem. 269:25830-25837.
8. Chaudry, G. J., M. Moayeri, S. Liu, and S. H. Leppla. 2002. Quickening the pace of anthrax research: three advances point towards possible therapies. Trends Microbiol. 10:58-62.
9. Dixon, T. C., M. Meselson, J. Guillemin, and P. C. Hanna. 1999. Anthrax. N. Engl. J. Med. 341:815-826.
10. Dua, V. K., N. C. Gupta, P. K. Kar, J. Nand, G. Edwards, V. P. Sharma, and S. K. Subbarao. 2000. Chloroquine and desethylchloroquine eoncentrations in blood cells and plasma from Indian patients infected with sensitive or resistant Plasmodium falciparum. Ann. Trop. Med. Parasitol. 94:565-570.
11. Duesbery, N. S., C. P. Webb, S. H. Leppla, V. M. Gordon, K. R. Klimpel, T. D. Copeland, N. G. Ahn, M. K. Oskarsson, K. Fukasawa, K. D. Paull, and G. F. Vande Woude. 1998. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 280:734-737.
12. Ferrari, V., and D. J. Cutler. 1987. Temperature dependence of the acid dissociation constants of chloroquine. J. Pharm. Sci. 76:554-556.
13. Fersht, A. R. 1985. Enzyme structure and mechanism, p. 106-107. W. H. Freeman and Co., New York, N.Y.
14. Friedlander, A. M. 1986. Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process. J. Biol. Chem. 261:7123-7126.
15. Friedlander, A. M., R. Bhatnagar, S. H. Leppla, L. Johnson, and Y. Singh. 1993. Characterization of macrophage sensitivity and resistance to anthrax lethal toxin. Infect. Immun. 61:245-252.
16. Gordon, V. M., K. R. Klimpel, N. Arora, M. A. Henderson, and S. H. Leppla. 1995. Proteolytic activation of bacterial toxins by eukaryotic cells is performed by furin and by additional cellular proteases. Infect. Immun. 63:82-87.
17. Gordon, V. M., S. H. Leppla, and E. L. Hewlett. 1988. Inhibitors of receptor-mediated endocytosis block the entry of Bacillus anthracis adenylate cyclase toxin but not that of Bordetella pertussis adenylate cyclase toxin. Infect. Immun. 56:1066-1069.
18. Gros, P., C. Betzel, Z. Dauter, K. S. Wilson, and W. G. Hol. 1989. Molecular dynamics refinement of a thermitase-eglin-c complex at 1.98 A resolution and comparison of two crystal forms that differ in calcium content. J. Mol. Biol. 210:347-367.
19. Holyoak, T., C. A. Kettner, G. A. Petsko, R. S. Fuller, and D. Ringe. 2004. Structural basis for differences in substrate selectivity in Kex2 and furin protein convertases. Biochemistry 43:2412-2421.
20. Holyoak, T., M. A. Wilson, T. D. Fenn, C. A. Kettner, G. A. Petsko, R. S. Fuller, and D. Ringe. 2003. 2.4 A resolution crystal structure of the prototypical hormone-processing protease Kex2 in complex with an Ala-Lys-Arg boronic acid inhibitor. Biochemistry 42:6709-6718.
21. Jagannathan, S., T. P. Forsyth, and C. A. Kettner. 2001. Synthesis of boronic acid analogues of alpha-amino acids by introducing side chains as electrophiles. J. Org. Chem. 66:6375-6380.
22. Jean, F., K. Stella, L. Thomas, G. Liu, Y. Xiang, A. J. Reason, and G. Thomas. 1998. α1-Antitrypsin Portland, a bioengineered serpin highly selective for furin: application as an antipathogenic agent. Proc. Natl. Acad. Sci. USA 95:7293-7298.
23. Kettner, C. A., and A. B. Shenvi. 1984. Inhibition of the serine proteases leukocyte elastase, pancreatic elastase, cathepsin G, and chymotrypsin by peptide boronic acids. J. Biol. Chem. 259:15106-15114.
24. Klimpel, K. R., S. S. Molloy, G. Thomas, and S. H. Leppla. 1992. Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin. Proc. Natl. Acad. Sci. USA 89:10277-10281.
25. Knight, C. G. 1986. The characterization of enzyme inhibition, p. 23-51. In A. J. Barrett and G. Salvesen (ed.), Proteinase inhibitors. Elsevier, Amsterdam, The Netherlands.
26. Komiyama, T., and R. S. Fuller. 2000. Engineered eglin c variants inhibit yeast and human proprotein processing proteases, Kex2 and furin. Biochemistry 39:15156-15165.
27. Komiyama, T., B. VanderLugt, M. Fugere, R. Day, R. J. Kaufman, and R. S. Fuller. 2003. Optimization of protease-inhibitor interactions by randomizing adventitious contacts. Proc. Natl. Acad. Sci. USA 100:8205-8210.
28. Krysan, D. J., N. C. Rockwell, and R. S. Fuller. 1999. Quantitative characterization of furin specificity. Energetics of substrate discrimination using an internally consistent set of hexapeptidyl methyleoumarinamides. J. Biol. Chem. 274:23229-23234.
29. Liu, S., and S. H. Leppla. 2003. Cell surface tumor endothelium marker 8 cytoplasmic tail-independent anthrax toxin binding, proteolytic processing, oligomer formation, and internalization. J. Biol. Chem. 278:5227-5234.
30. Mahmoud, B. M., H. M. Ali, M. M. Homeida, and J. L. Bennett. 1994. Significant reduction in chloroquine bioavailability following coadministration with the Sudanese beverages Aradaib, Karkadi and Lemon. J. Antimicrob. Chemother. 33:1005-1009.
31. Milne, J. C., D. Furlong, P. C. Hanna, J. S. Wall, and R. J. Collier. 1994. Anthrax protective antigen forms oligomers during intoxication of mammalian cells. J. Biol. Chem. 269:20607-20612.
32. Mock, M., and A. Fouet. 2001. Anthrax. Annu. Rev. Microbiol. 55:647-671.
33. Panchal, R. G., A. R. Hermone, T. L. Nguyen, T. Y. Wong, R. Schwarzenbacher, J. Schmidt, D. Lane, C. McGrath, B. E. Turk, J. Burnett, M. J. Aman, S. Little, E. A. Sausville, D. W, Zaharevitz, L. C. Cantley, R. C. Liddington, R. Gussio, and S. Bavari. 2004. Identification of small molecule inhibitors of anthrax lethal factor. Nat. Struct. Mol. Biol. 11:67-72.
34. Peinado, J. R., M. M. Kacprzak, S. H. Leppla, and I. Lindberg. 2004. Cross-inhibition between furin and lethal factor inhibitors. Biochem. Biophys. Res. Commun. 321:601-605.
35. Petosa, C., R. J. Collier, K. R. Kumpel, S. H. Leppla, and R. C. Liddington. 1997. Crystal structure of the anthrax toxin protective antigen. Nature 385:833-838.
36. Podsiadlo, P., T. Komiyama, R. S. Fuller, and O. Blum. 2004. Furin inhibition by compounds of copper and zinc. J. Biol. Chem. 279:36219-36227.
37. Rockwell, N. C., D. J. Krysan, T. Komiyama, and R. S. Fuller. 2002. Precursor processing by kex2/furin proteases. Chem. Rev. 102:4525-4548.
38. Sarac, M. S., J. R. Peinado, S. H. Leppla, and I. Lindberg. 2004. Protection against anthrax toxemia by hexa-D-arginine in vitro and in vivo. Infect. Immun. 72:602-605.
39. Singh, Y., V. K. Chaudhary, and S. H. Leppla. 1989. A deleted variant of Bacillus anthracis protective antigen is non-toxic and blocks anthrax toxin action in vivo. J. Biol. Chem. 264:19103-19107.
40. Taylor, W. R., and N. J. White. 2004. Antimalarial drug toxicity: a review. Drug Saf. 27:25-61.
41. Titus, E. O. 1989. Recent developments in the understanding of the pharmacokinetics and mechanism of action of chloroquine. Ther. Drug Monit. 11:369-379.
42. Turk, B. E., T. Y. Wong, R. Schwarzenbacher, E. T. Jarrell, S. H. Leppla, R. J. Collier, R. C. Liddington, and L. C. Cantley. 2004. The structural basis for substrate and inhibitor selectivity of the anthrax lethal factor. Nat. Struct. Mol. Biol. 11:60-66.